Brent Warner, President, Gene Therapy   Oct. 12 | 5:00pm | UBC Ballroom   San Diego, CA  (NASDAQ: PSTX)  In-person Presentation  Poseida Therapeutics is a clinical-stage biopharmaceutical company dedicated to utilizing its proprietary gene engineering platform technologies to create next generation cell and gene therapeutics with the capacity to cure. The company has discovered...

Leslie Meltzer, Ph.D., Chief Medical Officer  Oct. 12 | 4:15pm | UBC Ballroom  London, UK  (NASDAQ: ORTX)  In-person Presentation  At Orchard Therapeutics, our vision is to end the devastation caused by genetic and other severe diseases. We aim to do this by discovering, developing, and commercializing new treatments that tap into the...

Antonio Lee, Ph.D., CEO  Oct. 13 | 9:45am | Oxford Biomedica Ballroom  Vienna, VA  (Private)  In-person Presentation  MEDIPOST is a Korean-based company founded in 2000 which became a publicly traded company in 2005, listed on KOSDAQ with a $350 million market cap and 300 employees. The U.S. subsidiary is located in Virginia....

Jeff Liter, President and CEO  Oct. 12 | 11:00am | Oxford Biomedica Ballroom  Minneapolis, MN  (Private)  In-person Presentation  Luminary Therapeutics is a clinical-stage cell therapy company focused on combining advanced receptor design with superior cell engineering to overcome antigen escape and T cell dysfunction. Our novel ligand-based CAR is designed to...

Albert Seymour, Ph.D., President and CEO  Oct. 11 | 3:15pm | UBC Ballroom  Bedford, MA  (NASDAQ: FIXX)  In-person Presentation  Homology Medicines is a clinical-stage genetic medicines company dedicated to transforming the lives of patients suffering from rare diseases by addressing the underlying cause of the disease. Homology’s clinical programs include HMI-102, an...

Sunyoung Kim, CEO Oct. 11 | 2:45pm | UBC Ballroom   Seoul, Korea  (084990.KQ)  In-person Presentation  Introducing Helixmith’s ALS-Focused Program DART*: A novel, multimodal parallel approach exploiting HGF/c-Met Signaling. (*DART: Defeating ALS through Regenerative Therapeutics)Helixmith has established the ALS-Focused Program called DART. Our first platform capitalizes on the HGF/c-Met signaling pathway. Three modalities...

Richard Kincaid, Executive and Chief Financial Officer Oct. 11 | 5:00pm | UBC Ballroom   Tokyo, Japan  (TSE: 4593)  In-person Presentation  Healios K.K. is a biotechnology venture leading the field of regenerative medicine and cell therapy. It was founded in 2011 and listed on the Tokyo Stock Exchange in 2015. It aims to...

Kareem Reda, Chief Business Officer Oct. 12 | 4:30pm | Oxford Biomedica Ballroom   Waltham, MA  (Private)  In-person Presentation  ElevateBio is a technology-driven company built to power transformative cell and gene therapies today and for decades to come. The company has assembled industry-leading talent, built state-of-the-art facilities, and integrated diverse technology platforms,...

Ross Macdonald, Ph.D., CEO  Oct. 13 | 9:15am | Oxford Biomedica Ballroom  Melbourne, Australia  (ASX: CYP)  In-person Presentation  Cynata Therapeutics is a clinical-stage stem cell and regenerative medicine company developing a therapeutic mesenchymal stem cell (MSC) platform technology, Cymerus™, utilizing induced pluripotent stem cells (iPSCs) as starting material. A successful clinical trial...

Mark Sawicki, Ph.D., President and CEO Oct. 12 | 5:30pm | Oxford Biomedica Ballroom   Brentwood, TN  (NASDAQ: CYRX)  In-person Presentation  Cryoport Systems is a market leader in globally integrated temperature-controlled supply chain support for critical, irreplaceable products and materials in the life sciences industry. We are already trusted to support over 600...

By using this website you agree to accept our Privacy Policy and Terms & Conditions